Our future plan is to test the c-Rel-siRNA on other B cell tumors with constitutive c-Rel activation, including diffuse large B cell lymphoma, multiple myeloma, and chronic lymphocytic leukemia, in order to expand the uses of c-Rel-siRNA as potential therapy for these tumors. This evidence concerns the gene REL and plasma cell myeloma.